参考文献/References:
[1] GENCEL-AUGUSTO J,WU Wei,BIVONA T G.Long non-coding RNAs as emerging targets in lung cancer[J].Cancers,2023,15(12):3135.DOI:10.3390/cancers15123135.
[2] WANG Meibin,FU Yujie,ZHONG Chuyue,et al.Long non-coding RNA and evolving drug resistance in lung cancer[J].Heliyon,2023,9(12):e22591.DOI:10.1016/j.heliyon.2023.e22591.
[3] LIU Wenjuan,ZUO Bingli,LIU Wenting,et al.Long non-coding RNAs in non-small cell lung cancer: Implications for preventing therapeutic resistance[J].Biochimica et Biophysica Acta-Reviews on Cancer,2023,1878(6):188982.DOI:10.1016/j.bbcan.2023.188982
[4] GENG Yang,CHEN Pengfei,ZHANG Lei,et al.LncRNA MALAT1 regulates growth of carcinoma of the lung through modulating miR-338-3p/PYCR2 axis[J].Cellular and Molecular Biology,2023,69(4):133-140.DOI:10.14715/cmb/2023.69.4.21.
[5] CHEN Wenyu,TAN Xiaoli,YANG Qi,et al.MALAT1 enhances gemcitabine resistance in non-small cell lung cancer cells by directly affecting miR-27a-5p/PBOV1 axis[J].Cellular Signalling,2022,94:110326.DOI:10.1016/j.cellsig.2022.110326.
[6] SONG Jie,SU Zhengzhong,SHEN Qiming.Long non-coding RNA MALAT1 regulates proliferation, apoptosis, migration and invasion via miR-374b-5p/SRSF7 axis in non-small cell lung cancer[J].European Review for Medical and Pharmacological Sciences,2020,24(4):1853-1862.DOI:10.26355/eurrev_202002_20363.
[7] ZHANG Jun,WANG Mingliang,WANG Jiashun,et al.JMJD2C-mediated long non-coding RNA MALAT1/microRNA-503-5p/SEPT2 axis worsens non-small cell lung cancer[J].Cell Death & Disease,2022,13(1):65.DOI:10.1038/s41419-022-04513-5.
[8] HUANG Jinghua,LIN Changxiu,DONG Hai,et al.Targeting MALAT1 induces DNA damage and sensitize non-small cell lung cancer cells to cisplatin by repressing BRCA1[J].Cancer Chemotherapy and Pharmacology,2020,86(5):663-672.DOI:10.1007/s00280-020-04152-7.
[9] NIE Zhenkai,ZHANG Kaihua,LI Zhantao,et al.Human papillomavirus 16 E6 promotes angiogenesis of lung cancer via SNHG1[J].Cell Biochemistry and Biophysics,2023,81(2):325-336.DOI:10.1007/s12013-022-01121-0.
[10] ALNEFAIE G O.A review of the complex interplay between chemoresistance and lncRNAs in lung cancer[J].Journal of Translation Medicine,2024,22(1):1109.DOI:10.1186/s12967-024-05877-2.
[11] DU Yang,ZHU Shaowei,LIU Xianglu,et al.LncRNA HOTAIR regulates the expression of MRP1 gene through the mir-6807-5p/Egr1 axis to affect the multidrug resistance of lung cancer cells[J].Gene,2025,940:149216.DOI:10.1016/j.gene.2025.149216.
[12] LIANG Hanlin,PENG Jiewen.LncRNA HOTAIR promotes proliferation, invasion and migration in NSCLC cells via the CCL22 signaling pathway[J].Public Library of Science One,2022,17(2):e0263997.DOI:10.1371/journal.pone.0263997.
[13] LU Chenlin,LIU Jie,YANG Junfa.LncRNA-XIST promotes lung adenocarcinoma growth and inhibits ferroptosis by regulating GPX4[J].Molecular Biotechnology,2025,67(1):187-195.DOI:10.1007/s12033-023-00993-8.
[14] LI Cheng,SONG Shuai,WANG Yuge,et al.Deciphering the function of lncRNA XIST/miR-329-3p/TMBIM6 axis in the proliferation of non-small cell lung cancer[J].Journal of Investigative Surgery,2025,38(1):2457472.DOI:10.1080/08941939.2025.2457472.
[15] 高颖,罗小林,廖鹏飞,等.LncRNA NORAD通过miR-199a-3p调控ZNF217对非小细胞肺癌细胞增殖、凋亡及化疗敏感性的影响[J].中国肺癌杂志,2023,26(7):479-486.DOI:10.3779/j.issn.1009-3419.2023.102.27.
[16] MA Jianqun,ZHANG Ping,WANG Yuning,et al.LncRNA HAR1A inhibits non-small cell lung cancer growth by downregulating c-MYC transcripts and facilitating its proteasomal degradation[J].International Immunopharmacology,2024,142:113264.DOI:10.1016/j.intimp.2024.113264.
[17] LIU Zhile,WANG Qi,BI Yue,et al.Long non-coding RNA DINO promotes cisplatin sensitivity in lung adenocarcinoma via the p53-Bax axis[J].Journal of Thoracic Disease,2023,15(4):2198-2212.DOI:10.21037/jtd-23-465.
[18] SHE Kelin,HE Shushuai,LU Xiao,et al.LncRNA SNHG7 promotes non-small cell lung cancer progression and cisplatin resistance by inducing autophagic activity[J].Journal of Thoracic Disease,2023,15(1):155-167.DOI:10.21037/jtd-22-1826.
[19] HUANG Fengxiang,CHEN Hongjie,ZHENG Fuxia,et al.LncRNA BLACAT1 is involved in chemoresistance of non small cell lung cancer cells by regulating autophagy[J].International Journal of Oncology,2019,54(1):339-347.DOI:10.3892/ijo.2018.4614.
[20] ZHU Feng,NIU Rong,SHAO Xiaoliang,et al.FGD5 AS1 promotes cisplatin resistance of human lung adenocarcinoma cell via the miR1425p/PDL1 axis[J].International Journal of Molecular Medicine,2021,47(2):523-532.DOI:10.3892/ijmm.2020.4816.
[21] LIU Xuehui,ZHANG Xufeng,DU Shuzhang.Long non-coding RNA ACTA2-AS1 inhibits the cisplatin resistance of non-small cell lung cancer cells through inhibiting autophagy by suppressing TSC2[J].Cell Cycle,2022,21(4):368-378.DOI:10.1080/15384101.2021.2020433.
[22] LI Yong,HUANG Huiqin,HUANG Zhenghui,et al.SNHG15 enhances cisplatin resistance in lung adenocarcinoma by affecting the DNA repair capacity of cancer cells[J].Diagnostic Pathology,2023,18(1):33.DOI:10.1186/s13000-023-01291-2.
[23] HUSSAIN M S,AFZAL O,GUPTA G,et al.Unraveling NEAT1’s complex role in lung cancer biology: A comprehensive review[J].EXCLI Journal,2024,23:34-52.DOI:10.17179/excli2023-6553.
[24] ZHUO Ting,WU Zuotao,YANG Chuyi,et al.LncRNA CERS6-AS1 upregulates the expression of ANLN by sponging miR-424-5p to promote the progression and drug resistance of lung adenocarcinoma[J].Non-coding RNA Research,2024,9(1):221-235.DOI:10.1016/j.ncrna.2023.11.013.
[25] SHEN Qiming,WANG Haoyou,ZHANG Lin.TP63 functions as a tumor suppressor regulated by GAS5/miR-221-3p signaling axis in human non-small cell lung cancer cells[J].Cancer Management and Research,2023,15:217-231.DOI:10.2147/cmar.S387781.
[26] YANG Xuhui,MENG Lifei,ZHONG Yuang,et al.The long intergenic noncoding RNA GAS5 reduces cisplatin-resistance in non-small cell lung cancer through the miR-217/LHPP axis[J].Aging,2021,13(2):2864-2884.DOI:10.18632/aging.202352.
[27] 范喜瑞,戚之琳,邓园洁,等.LncRNA MAGI2-AS3通过靶向调控miR-1269a/PTEN/AKT通路增强非小细胞肺癌对顺铂化疗的敏感性[J].南方医科大学学报,2024,44(10):2033-2043.DOI:10.12122/j.issn.1673-4254.2024.10.22.
[28] YIN Hang,CHEN Lin,PIAO Shiqi,et al.M6A RNA methylation-mediated RMRP stability renders proliferation and progression of non-small cell lung cancer through regulating TGFBR1/SMAD2/SMAD3 pathway[J].Cell Death and Differentiation,2023,30(3):605-617.DOI:10.1038/s41418-021-00888-8.
[29] ZHENG Yu,GUO Ziyi,LI Ying.Long non-coding RNA prostate cancer-associated transcript 6 inhibited gefitinib sensitivity of non-small cell lung cancer by serving as a competing endogenous RNA of miR-326 to up-regulate interferon-alpha receptor 2[J].Bioengineered,2022,13(2):3785-3796.DOI:10.1080/21655979.2022.2031416.
[30] ZUO Tao,JIANG Ping,FU Jun,et al.LncRNA AFAP1-AS1 induces gefitinib resistance of lung adenocarcinoma through the miR-653-5p/AGR2 axis[J].Therapeutic and Clinical Risk Management,2023,19:1-13.DOI:10.2147/tcrm.S374162.
[31] TANG Qing,ZHOU Qichun,LI Jing,et al.Solamargine enhanced gefitinib antitumor effect via regulating MALAT1/miR-141-3p/Sp1/IGFBP1 signaling pathway in non-small cell lung cancer[J].Carcinogenesis,2023,44(6):497-510.DOI:10.1093/carcin/bgad028.
[32] DARVISH M.LncRNA FTH1P3: A new biomarker for cancer-related therapeutic development[J].Current Molecular Medicine,2024,24(5):576-584.DOI:10.2174/1566524023666230724141353.
[33] ZHANG Heng,WANG Shaoqiang,WANG Li,et al.m6A methyltransferase METTL3-induced lncRNA SNHG17 promotes lung adenocarcinoma gefitinib resistance by epigenetically repressing LATS2 expression[J].Cell Death & Disease,2022,13(7):657.DOI:10.1038/s41419-022-05050-x.
[34] JIA Mingxi,FENG Shanshan,CAO Fengxi,et al.Identification of EGFR-Related LINC00460/mir-338-3p/MCM4 regulatory axis as diagnostic and prognostic biomarker of lung adenocarcinoma based on comprehensive bioinformatics analysis and experimental validation[J].Cancers,2022,14(20):5073.DOI:10.3390/cancers14205073.
[35] DAI Jiali,QU Tianyu,YIN Dandan,et al.LncRNA LINC00969 promotes acquired gefitinib resistance by epigenetically suppressing of NLRP3 at transcriptional and posttranscriptional levels to inhibit pyroptosis in lung cancer[J].Cell Death & Disease,2023,14(5):312.DOI:10.1038/s41419-023-05840-x.
[36] ZHONG Chenming,XIE Zijun,SHEN Jinze,et al.LINC00665: An emerging biomarker for cancer diagnostics and therapeutics[J].Cells,2022,11(9):1540.DOI:10.3390/cells11091540.
[37] CHEN Huaxin,SHEN Dan,ZHU Feng,et al.Long noncoding RNA RP11-89K21.1 interacts with miR-146a/b-5p to promote proliferation and gefitinib resistance through regulating RHPN2 and RhoA/ROCK pathway in lung adenocarcinoma[J].Cancer Biotherapy and Radiopharmaceuticals,2023,38(5):282-292.DOI:10.1089/cbr.2020.4395.
[38] LIU Wenjing,DUAN Zhipeng,WU Yefeng,et al.Silencing of lncRNA LOC105376794 promotes migration, invasion, and Gefitinib resistance of lung adenocarcinoma cells with EGFR 19Del mutation by ATF4/CHOP axis and ERK phosphorylation[J].Neoplasma,2024,71(3):219-230.DOI:10.4149/neo_2024_230616N316.
[39] XU Cong,JIANG Zebo,SHAO Le,et al.β-Elemene enhances erlotinib sensitivity through induction of ferroptosis by upregulating lncRNA H19 in EGFR-mutant non-small cell lung cancer[J].Pharmacological Research,2023,191:106739.DOI:10.1016/j.phrs.2023.106739.
[40] CHEN Bohang,ZHANG Bohao,GARCíA CENADOR M B.Human bone marrow mesenchymal stem cell-driven lncRNA PTCSC3 upregulation within lung adenocarcinoma cells reduces erlotinib resistance by mitigating Wnt/β-catenin pathway[J].American Journal of Cancer Research,2024,14(5):2439-2452.DOI:10.62347/bofp2157.
[41] NAKANO Y,ISOBE K,YOSHIZAWA T,et al.Upregulation of long non coding RNA LINC00460 in EGFR mutant lung cancer indicates a poor prognosis in patients treated with osimertinib[J].Oncology Letters,2023,26(3):380.DOI:10.3892/ol.2023.13966.
[42] LEI Quan,LIU Ping,GUAN Xinlei,et al.Silencing of LINC01278 promotes sensitivity of non-small cell lung cancer cells to osimertinib by targeting miR-324-3p/ZFX axis[J].Cytotechnology,2025,77(1):23.DOI:10.1007/s10616-024-00673-8.
[43] DING Dandan,XU Chenguang,ZHANG Jufeng,et al.Revealing underlying regulatory mechanisms of LINC00313 in Osimertinib-resistant LUAD cells by ceRNA network analysis[J].Translational Oncology,2024,43:101895.DOI:10.1016/j.tranon.2024.101895.
[44] YANG Yan,JIANG Caiyu,YANG Yang,et al.Silencing of lncRNA-HOTAIR decreases drug resistance of non-small cell lung cancer cells by inactivating autophagy via suppressing the phosphorylation of ULK1[J].Biochemical and Biophysical Research Communications,2018,497(4):1003-1010.DOI:10.1016/j.bbrc.2018.02.141.
[45] YANG Kaixin,ZHANG Wenyang,ZHONG Linghui,et al.Long non-coding RNA HIF1A-As2 and MYC form a double-positive feedback loop to promote cell proliferation and metastasis in KRAS-driven non-small cell lung cancer[J].Cell Death and Differentiation,2023,30(6):1533-1549.DOI:10.1038/s41418-023-01160-x.
[46] XU Dexin,WANG Wenhai,WANG Duo,et al.Long noncoding RNA MALAT-1: A versatile regulator in cancer progression, metastasis, immunity, and therapeutic resistance[J].Non-Coding RNA Research,2024,9(2):388-406.DOI:10.1016/j.ncrna.2024.01.015.
[47] CHEN Xiujuan,ZHANG Le.Integrative analysis revealed LINC00847 as a potential target of tumor immunotherapy[J].Applied Biochemistry and Biotechnology,2023,195(10):6345-6358.DOI:10.1007/s12010-023-04387-z.
[48] QIAO Xinwei,ZHAO Feng.Long non-coding RNA Opa interacting protein 5-antisense RNA 1 binds to micorRNA-34a to upregulate oncogenic PD-L1 in non-small cell lung cancer[J].Bioengineered,2022,13(4):9264-9273.DOI:10.1080/21655979.2022.2036904.
[49] HUANG Yusheng,XIA Lei,TAN Xiangwu,et al.Molecular mechanism of lncRNA SNHG12 in immune escape of non-small cell lung cancer through the HuR/PD-L1/USP8 axis[J].Cellular and Molecular Biology Letters,2022,27(1):43.DOI:10.1186/s11658-022-00343-7.